Guidance

Actions to contain carbapenemase-producing Enterobacterales (CPE)

This framework focuses on carbapenemase-producing Enterobacterales that spread rapidly in healthcare settings.

From:
UK Health Security Agency
Published
1 October 2020
Last updated
28 September 2022 鈥� See all updates

Documents

Ref: UKHSA publications gateway number GOV-10737

PDF, 785 KB, 78 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

皇冠体育app increased incidence of carbapenemase-producing Enterobacterales (CPE) has significant cost and operational implications for healthcare providers.

Unless action is taken and we learn from experiences elsewhere in the world, rapid spread of CPE will pose an ever-increasing threat to public health and medical treatment pathways in the UK.

皇冠体育app framework sets out a range of measures, that if implemented well, will help health and social care providers minimise the impact of CPE.

Updates to this page

Published 1 October 2020
Last updated 28 September 2022 show all updates

  1. Added updated framework and changed branding to UKHSA.

  2. First published.

Sign up for emails or print this page

Related content